GSBR-1290

DRUG3 trials

Sponsors

Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

Conditions

Healthy VolunteersOverweight or ObesityType2 Diabetes Mellitus

Phase 1

Phase 1b/2a Study of GSBR-1290 in Adult Overweight or Obese Healthy Subjects and Subjects With Type 2 Diabetes Mellitus

CompletedNCT05762471

Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure TherapeuticsOverweight or Obesity, Type2 Diabetes Mellitus

Start: 2023-01-09End: 2024-04-11Updated: 2024-04-25

A Study of Multiple Ascending Doses of GSBR-1290 in Japanese and Non-Japanese Healthy Participants

CompletedNCT05893043

Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure TherapeuticsHealthy Volunteers

Start: 2023-04-24End: 2023-06-28Updated: 2023-07-14

A Study of Multiple-ascending Doses of GSBR-1290 in Healthy Overweight/Obese Participants

Active, not recruitingNCT06139055

Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure TherapeuticsHealthy Volunteers

Start: 2023-10-02End: 2024-03-31Updated: 2024-02-15